NSABP – Contact Details
Country
USA
Chair
N. Wolmark, National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, PITTSBURGH, PA 15212-5234, USA. Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Other Subgroup Head/Member(s)
NSABP Operations Center, East Commons Professional Building, Four Allegheny Center, 5th Floor, PITTSBURGH, PA 15212–5234, USA.
Chief Executive Officer
J. Goldberg, Tel: +1 412 330 4601 Fax: +1 412 330 4660 Email: [email protected]
Chief Financial Officer
R. Jones, Tel: +1 412 330 4673 Fax: +1 412 330 4660 Email: [email protected]
Associate Chair
M. O'Connell, Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Associate Chair/Director of Operations
D. Lawrence Wickerham, Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
C. Geyer, Jr. Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Division of Membership Affairs
M. Ketner, Tel: +1 412 330 4624 Fax: +1 412 330 4661 Email: [email protected]
Division of Regulatory Affairs
J. Mull, Tel: +1 412 330 4625 Fax: +1 412 330 4661 Email: [email protected]
Clinical Coordinating Division
L. Suhayda, Tel: +1 412 330 4634 Fax: +1 412 330 4660 Email: [email protected]
Division of Protocol Development and Management
B. Harkins, Tel: +1 412 330 4643 Fax: +1 412 330 4660 Email:[email protected]
Division of Scientific Publications
B. Good, Tel: +1 412 330 4639 Fax: +1 412 330 4660 Email: [email protected]
Division of Public Relations and Communications
L. Garvey. Tel: +1 412 330 4621 Fax: +1 412 330 4645 Email: [email protected]
Division of Finance and Sponsored Projects
D. Szczepankowski, Tel: +1 412 330 4610 Fax: +1 412 330 4260 Email: [email protected]
Other Subgroup Head/Member
J. Costantino, NSABP Biostatistical Center, One Sterling Plaza, 201 North Craig St., Suite 500, PITTSBURGH, PA 15213, USA. Tel: +1 412 383 2638 Fax: +1 412 383 1387 Email: [email protected]
Other Subgroup Head/Member
W. Curran, B-39 RTOG Group Chair, American College of Radiology, 1818 Market St., Suite 1600, PHILADELPHIA, PA 19103, USA. Tel: +1 215 574 3189 Fax: +1 215 928 0153
Website
NSABP – Study Details
Title
NSABP B-35 – A clinical trial comparing anastrozole with tamoxifen in postmenopausal patients with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy.
Coordinator(s) Principal Investigator
N. Wolmark, National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, PITTSBURGH, PA 15212-5234, USA. Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Summary
- Opened on 6 January 2003
- Target accrual: 3000 patients
Objectives
- To compare the value of 1 mg/day of anastrozole to 20 mg/day of tamoxifen, each given for 5 years, in preventing the subsequent occurrence of breast cancer (local, regional and distant recurrences, and contralateral breast cancer) following lumpectomy with radiation therapy in postmenopausal women with ductal carcinoma in situ (DCIS).
- To compare the quality of life of the patients between the two arms.
- To compare the two arms in terms of osteoporotic fractures.
- To compare the two arms in terms of future malignancies.
- To compare the two arms in terms of disease free survival and overall survival.
Scheme
Arm I: Tamoxifen + placebo + breast radiation therapy
Arm II: Anastrozole + placebo + breast radiation therapy
Update
- 3104 patients have been accrued through June 2006.
- Patient accrual closed June 2006.
Related Publications
None available
Topics
- DCIS
- Postmenopausal patients
- Predictive markers
- Hormonal therapy
- Aromatase inhibitors
- Radiotherapy
Keywords
DCIS, postmenopausal patients, predictive markers, hormonal therapy, aromatase inhibitors, radiotherapy
***************************************************
Title
NSABP B-36 – A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.
Coordinator(s): Principal Investigator
N. Wolmark, National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, PITTSBURGH, PA 15212-5234, USA. Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Summary
- Opened to accrual on 20 May 2004
- Target accrual: 2700
Objectives
- To determine superiority between four cycles of AC and six cycles of FEC for prolonging disease-free survival in women with node-negative breast cancer.
- To determine superiority among the proposed regimens for prolonging survival (S), recurrence-free interval (RFI), and distant recurrence-free interval (DRFI) in this population.
- To compare the adverse events between four cycles of AC and six cycles of FEC.
- To compare the adverse events within the proposed regimens administered with celecoxib or placebo in patients enrolled prior to suspension of celecoxib/placebo randomization on 17/12/04.
- To describe the differences in symptoms and quality of life between the chemotherapy regimens.
- To assess the rates of post-chemotherapy amenorrhea in premenopausal women.
- To examine the relationship between change in LVEF and self-reported physical functioning.
- To evaluate if six cycles of FEC is superior to four cycles of AC in cases in which HER-2 and/or Topo-II genes are amplified.
Scheme
Arm 1: Four cycles of adriamycin and cyclophosphamide
Arm 2: Six cycles of 5-fluorouracil, epirubicin and cyclophosphamide
Update
- 1625 patients have been accrued through September 2006.
Related Publications
None available
Topics
- Node-negative breast cancer
- Predictive markers
- Cardiac funciton
- Menstrual cycle
Keywords
Node-negative breast cancer, predictive markers, cardiac function, menstrual cycle
***************************************************
Title
NSABP B-38 – A phase III, adjuvant trial comparing three chemotherapy regimens in women with node-positive breast cancer: docetaxel/doxorubicin/cyclophosphamide (TAC); dose-dense (DD) doxorubicin/cyclophosphamide followed by DD paclitaxel (DD AC→P): DD AC followed by DD paclitaxel plus gemcitabine (DD AC→PG).
Coordinator(s): Principal Investigator
N. Wolmark, National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, PITTSBURGH, PA 15212-5234, USA. Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Summary
- Opened to accrual on 1 October 2004
- Target accrual: 4800
Objectives
- To determine whether the dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel plus gemcitabine regimen (DD AC→PG) is superior to the docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen as well as to the dose-dense doxorubicin and cyclophosphamide (AC)→dose-dense paclitaxel regimen (DD AC→P) in improving disease-free survival (DFS).
- To compare the relative DFS of docetaxel, doxorubicin, and cyclophosphamide (TAC) and dose-dense doxorubicin/ cyclophosphamide followed by dose-dense paclitaxel alone (DD AC→P).
- To determine whether the dose-dense doxorubicin/cyclophosphamide followed by dose-dense paclitaxel plus gemcitabine regimen is superior to the docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen as well as to dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel regimen in improving survival (S), recurrence-free interval (RFI), and distant recurrence-free interval (DRFI).
- To compare S, RFI, and DRFI of the docetaxel, doxorubicin, and cyclophosphamide (TAC) and dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel regimens (DD AC→P).
- To compare the toxicities of the three regimens.
Scheme
Arm 1: Doxorubicin, cyclophosphamide, and docetaxel once every 21 days for six visits.
Arm 2: Doxorubicin and cyclophosphamide through a vein once every 14 days for four visits.Fourteen days after the last treatment with these two chemotherapy drugs, patients will begin to receive paclitaxel once every 14 days for four visits.
Arm 3: Doxorubicin and cyclophosphamide through a vein once every 14 days for four visits.Fourteen days after the last treatment with these two chemotherapy drugs, patients will begin to receive paclitaxel and gemcitabine once every 14 days for four visits.
Update
- 3513 patients have been accrued through September 2006.
Related Publications
None available
Topics
- Dose densification
- Predictive markers
- Node-negative breast cancer
- Gemcitabine
- Anthracyclines
- Taxanes
Keywords
Dose densification, predictive markers, node-negative breast cancer, gemcitabine, anthracyclines, taxanes
***************************************************
Title
NSABP B-39 – A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer.
Coordinator(s): Principal Investigator
N. Wolmark, National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, PITTSBURGH, PA 15212-5234, USA. Tel: +1 412 330 4600 Fax: +1 412 330 4660 Email: [email protected]
Summary
- Opened to accrual on 21 March 2005
- Target accrual: 3000
Objectives
- To determine whether PBI limited to the region of the tumor bed following lumpectomy provides equivalent local tumor control in the breast compared to conventional WBI in the local management of early stage breast cancer.
- To compare PBI and WBI in terms of overall survival, recurrence free survival, distant disease-free survival, cosmetic results, fatigue and treatment-related symptoms, and perceived convenience of care.
Scheme
Arm 1: Whole breast irradiation
Arm 2: Partial breast irradiation (multi-catherter brachytherapy, MammoSite, or 3D conformal external beam radiation)
Update
- 2034 patients have been accrued through September 2006.
Related Publications
None available
Topics
- Radiation therapy
- Breast conservation treatment
Keywords
Radiation therapy, breast conservative treatment
